Abstract
X-ray computed tomography (CT), an efficient non-invasive clinical technique, usually provides highresolution 3D structure details of tissues in early disease diagnosis. Here, we report a high-performance CT imaging platform based on a monodispersed Yb-based nanoparticulate contrast agent. The well-prepared nanoprobes presented excellent in vitro and in vivo performances in the CT imaging, very low cytotoxicity and no detectable tissue damage in one month. More significantly, compared with routinely used Iobitridol in clinic, our Yb-based CT contrast agents provided much more enhanced contrast at a clinical 120 kVp voltage. Additionally, these nanoparticulate contrast agent could be excreted mainly via feces and urine, indicating the total elimination from the animal bodies and more potential for further biomedical applications.
Keywords: Yb-based nanoparticles, imaging agent, biocompatibility, large-scale synthesis, biomedicine.
Current Topics in Medicinal Chemistry
Title:Large-Scale and Facile Synthesis of Biocompatible Yb-Based Nanoparticles as a Contrast Agent for In Vivo X-Ray Computed Tomography Imaging
Volume: 13 Issue: 4
Author(s): Jianhua Liu, Rui Xin, Zhiman Li, Reza Golamaully, Yan Zhang, Jishen Zhang, Qinghai Yuan and Xiaodong Liu
Affiliation:
Keywords: Yb-based nanoparticles, imaging agent, biocompatibility, large-scale synthesis, biomedicine.
Abstract: X-ray computed tomography (CT), an efficient non-invasive clinical technique, usually provides highresolution 3D structure details of tissues in early disease diagnosis. Here, we report a high-performance CT imaging platform based on a monodispersed Yb-based nanoparticulate contrast agent. The well-prepared nanoprobes presented excellent in vitro and in vivo performances in the CT imaging, very low cytotoxicity and no detectable tissue damage in one month. More significantly, compared with routinely used Iobitridol in clinic, our Yb-based CT contrast agents provided much more enhanced contrast at a clinical 120 kVp voltage. Additionally, these nanoparticulate contrast agent could be excreted mainly via feces and urine, indicating the total elimination from the animal bodies and more potential for further biomedical applications.
Export Options
About this article
Cite this article as:
Liu Jianhua, Xin Rui, Li Zhiman, Golamaully Reza, Zhang Yan, Zhang Jishen, Yuan Qinghai and Liu Xiaodong, Large-Scale and Facile Synthesis of Biocompatible Yb-Based Nanoparticles as a Contrast Agent for In Vivo X-Ray Computed Tomography Imaging, Current Topics in Medicinal Chemistry 2013; 13 (4) . https://dx.doi.org/10.2174/1568026611313040011
DOI https://dx.doi.org/10.2174/1568026611313040011 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions
Current Drug Metabolism Effects of Bioactive Peptide on Inflammatory Bowel Disease, Focus on Signal Transduction and Intestinal Microbiota
Current Pharmaceutical Design An Insight to Colon Targeted Drug Delivery System
Drug Delivery Letters G-Protein Coupled Receptor 124 (GPR124) in Endothelial Cells Regulates Vascular Endothelial Growth Factor (VEGF)-Induced Tumor Angiogenesis
Current Molecular Medicine A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Mucosal Vaccine Vectors: Replication-Competent Versus Replication-Deficient Poxviruses
Current Pharmaceutical Design Covalently and Ionically Crosslinked Chitosan Nanogels for Drug Delivery
Current Pharmaceutical Design IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment
Current Drug Metabolism A Meta-Analysis of Proteomic Blood Markers of Colorectal Cancer
Current Medicinal Chemistry Evaluation of Novel Radioiodinated C7-substituted Δ6,7 – estradiol Derivatives for Molecular Recognition of ER-Positive Breast Tumours
Current Radiopharmaceuticals Purification and Characterization of a Novel Anti-Proliferative Lectin from Morus alba L. Leaves
Protein & Peptide Letters Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Managing Expectations in the Transition to Proof of Concept Studies
Reviews on Recent Clinical Trials A Review of Light Sources and Enhanced Targeting for Photodynamic Therapy
Current Medicinal Chemistry Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
Current Neuropharmacology Anti-IL-12/23 in Crohn's Disease: Bench and Bedside
Current Drug Targets Applications of Mesoporous Materials as Excipients for Innovative Drug Delivery and Formulation
Current Pharmaceutical Design